Healthcare
Live Price
Offline$15.30
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rhoen-Klinikum AG (RHKJF) is a Healthcare stock with a market cap of $830.00M and listed on OTC. The stock last traded around $15.30 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +21.3%, EPS growth of -23.9%, a dividend yield of 0.8%. What stands out right now is revenue +21.3%, EPS -23.9%, free cash flow -160.5% with operating margin 2.4% and ROIC 2.2%. The dividend is present but secondary, with a yield around 0.8%. Valuation is more restrained than many high-expectation growth names at P/E 24.1 and price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RHKJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RHKJF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RHKJF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RHKJF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.6B
+10.0% YoY
FY Net Income
$28.3M
+12.5% YoY
Free Cash Flow
$19.7M
+838.1% YoY
Revenue Growth
+21.3%
EPS Growth
-23.9%
Gross Margin
15.7%
Net Margin
2.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.6B | 1.7B | 1.4B | 1.6B |
| Gross Profit | 168M | 172M | 203M | 1000M | 183M |
| Operating Income | 4M | 48M | 40M | 36M | 31M |
| EBITDA | 69M | 122M | 117M | 107M | 100M |
| Net Income | 34M | 43M | 39M | 25M | 28M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 170M | 280M | 206M | 77M | 126M |
| Total Assets | 1.8B | 1.9B | 1.8B | 1.7B | 1.7B |
| Total Liabilities | 467M | 531M | 490M | 454M | 441M |
| Shareholder Equity | 1.3B | 1.3B | 1.3B | 1.2B | 1.2B |
| Total Debt | 122M | 150M | 150M | 158M | 160M |
| Net Debt | -48M | -130M | -56M | 81M | 33M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
98M
+61.7% YoY
Capital Expenditures
78M
-33.7% YoY
Free Cash Flow
20M
+838.1% YoY
Key ratios
Gross Margin
15.7%
Operating Margin
2.4%
Net Margin
2.0%
ROE
2.6%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.